Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 1 study of anti-IGF-IR CP-751,871 in patients with solid tumors currently enrolling patients 9 years old and older with Ewing's sarcoma family of tumors (Ewing's, PNET and Askin's).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Diagnosis of Ewing's sarcoma family tumors

Exclusion Criteria:

• Concurrent treatment with any other anti tumor agents